| 05th week of 2010 patent applcation highlights part 55 |
| Patent application number | Title | Published |
|---|
| 20100029496 | Multiplexed lateral flow microarray assay for detection of citrus pathogens Xylella fastidiosa and Xanthomonas axonopodis PV citri - The invention provides highly sensitive and specific assays for the major citrus pathogens | 2010-02-04 |
| 20100029497 | METHOD FOR ENGINEERING IMMUNOGLOBULINS - The present invention relates to a method for engineering an immunoglobulin comprising a variable domain and at least one modification in at least two structural loops of said immunoglobulin and determining the binding of said immunoglobulin to an epitope of an antigen, wherein the unmodified immunoglobulin does not significantly bind to said epitope, comprising the steps of: providing a nucleic acid encoding an immunoglobulin comprising at least two structural loops, modifying at least one nucleotide residue of each of said structural loops, transferring said modified nucleic acid in an expression System, expressing said modified immunoglobulin, contacting the expressed modified immunoglobulin with an epitope, and determining whether said modified immunoglobulin binds to said epitope, immunoglobulins produced by such a method and libraries of immunoglobulins. | 2010-02-04 |
| 20100029498 | SELECTION OF NUCLEIC ACIDS BY SOLUTION HYBRIDIZATION TO OLIGONUCLEOTIDE BAITS - Methods of selection of nucleic acids using solution hybridization, methods of sequencing nucleic acids including such selection methods, and products for use in the methods are disclosed. | 2010-02-04 |
| 20100029499 | Artificial Protein Scaffolds - The present invention provides proteins having one or more similarities to the artificial protein Top7 or to a Top7 derivative. Proteins of the invention have one or more loops that are longer than the corresponding loops of Top7, and/or that bind to a preselected target molecule. The invention also provides nucleic acids and cells useful in producing the proteins and methods for their use. | 2010-02-04 |
| 20100029500 | OLIGONUCLEOTIDE ARRAYS TO MONITOR GENE EXPRESSION AND METHODS FOR MAKING AND USING SAME - The present invention provides an oligonucleotide array capable of identifying genes and related pathways involved with the induction of a particular phenotype by a cell line, e.g., the genes and related pathways involved with the induction of transgene expression by the cell line. The invention is particularly useful when there is little or no information about the genome of the cell line being studied, because it provides methods for identifying consensus sequences for known and previously undiscovered genes, and for designing oligonucleotide probes to the identified consensus sequences. Additionally, when the array is to be used to determine optimal conditions for expression of a transgene by the cell line, the invention teaches methods of including oligonucleotide probes to transgene sequences in the array. The invention also provides methods of using the array to identify genes and related pathways involved with the induction of a particular cell line phenotype. The invention also provides novel polynucleotides of undiscovered genes (i.e., a gene that had not been sequenced and/or shown to be expressed by CHO cells) and novel polynucleotides involved with the induction of a particular cell phenotype, e.g., increased survival when grown under stressful culture conditions, increased transgene expression, decreased production of an antigen, etc. These novel polynucleotides are termed novel CHO sequences and differential CHO sequences, respectively. The invention also provides genetically engineered expression vectors, host cells, and transgenic animals comprising the novel nucleic acid molecules of the invention. The invention additionally provides antisense and RNAi molecules to the nucleic acid molecules of the invention. The invention further provides methods of using the polynucleotides of the invention. | 2010-02-04 |
| 20100029501 | METHOD OF IDENTIFYING MICRO-RNA TARGETS - The present invention provides methods of identifying an mRNA target of a microRNA. The present invention further provides kits and systems for carrying out a subject method. | 2010-02-04 |
| 20100029502 | Self-Assembly of Molecules Using Combinatorial Hybridization - Simple and convenient methods for arranging molecules of interest in a pre-determined pattern are described. The methods use combinatorial hybridization based on interactions between complementary nucleic acid sequences to arrange the molecules of interest. The resulting arrangements, kits containing the components used in the methods, and methods of using the resulting arrangements are also disclosed. | 2010-02-04 |
| 20100029503 | ANALYSIS CHIP AND ANALYSIS METHOD - This invention is directed to an analysis chip comprising a substrate having a surface on which a selective binding substance is immobilized; a cover member adhered to the substrate; and particles movably contained or injected in a void between the substrate and the cover member; wherein the surfaces of the particles are coated with a surfactant. By this invention, generation of bubbles which inhibit the selective reaction between the test substance and the immobilized selective binding substance is suppressed, thereby reducing the deviation of data, suppressing the lowering of sensitivity, and promoting the reproducibility of the measurement. | 2010-02-04 |
| 20100029504 | DETECTING PAX2 FOR THE DIAGNOSIS OF BREAST CANCER - A method for monitoring breast conditions in a subject is disclosed. The method comprises determining a Paired Box 2 gene-to-beta defensin- | 2010-02-04 |
| 20100029505 | shRNA library - As noted above, certain aspects of this disclosure relate to a library of nucleic acid vectors, as well as a method for making the same. In certain embodiments, the library of nucleic acid vectors comprises: a plurality of nucleic acid molecules of the following formula: S | 2010-02-04 |
| 20100029506 | Label-Free Monitoring of Excitation-Contraction Coupling and Excitable Cells Using Impedance Based Systems with Millisecond Time Resolution - Systems and methods for improved monitoring of excitation-contraction coupling and excitable cells are provided, which provide millisecond time resolution. The system is capable of continuously monitoring excitation-contraction coupling in a relatively high-throughput manner. The system includes a device for monitoring cell-substrate impedance, an impedance analyzer capable of impedance measurements at millisecond time resolution, electronic circuitry that can engage the device and selectively connect two or more electrode arrays of the device to the impedance analyzer and a software program that controls the electronic circuitry and records and analyzes data obtained from the impedance analyzer. | 2010-02-04 |
| 20100029507 | THE BIOCHIP FOR THE DETECTION OF PHOSPHORYLATION AND THE DETECTION METHOD USING THE SAME - The present invention relates to a biochip for the detection of phosphorylation and a method for measuring phosphorylation using the same, more precisely a biochip integrated with the substrate of kinase and a kit for measuring phosphorylation comprising the biochip and a radio-labeled co-factor, and a method for measuring phosphorylation using the same. The kit for the detection of phosphorylation of the present invention facilitates simple and fast measurement of phosphorylation with a minimum amount of a sample, compared with the conventional method using an antibody, because it uses a radioisotope. This chip and kit can be effectively used for the analysis of kinase activity since this method favors fast mass analysis. | 2010-02-04 |
| 20100029508 | NANOCHANNEL ARRAYS AND THEIR PREPARATION AND USE FOR HIGH THROUGHPUT MACROMOLECULAR ANALYSIS - Nanochannel arrays that enable high-throughput macromolecular analysis are disclosed. Also disclosed are methods of preparing nanochannel arrays and nanofluidic chips. Methods of analyzing macromolecules, such as entire strands of genomic DNA, are also disclosed, as well as systems for carrying out these methods. | 2010-02-04 |
| 20100029509 | NOVEL METHODS - The present invention relates to novel methods for producing a biosensor for detecting a specific compound, for identifying a gene encoding a regulatory protein responsive to a specific compound and for identifying a gene encoding a regulatory protein responsive to a specific compound. | 2010-02-04 |
| 20100029510 | siRNA targeting survivin - Efficient sequence specific gene silencing is possible through the use of siRNA technology. By selecting particular siRNAs by rationale design, one can maximize the generation of an effective gene silencing reagent, as well as methods for silencing genes. Through these methodologies, one can select siRNA that target genes, including surviving. | 2010-02-04 |
| 20100029511 | CDNA SYNTHESIS USING NON-RANDOM PRIMERS - The present invention provides methods for selectively amplifying a target population of nucleic acid molecules in a population of RNA template molecules (e.g., all mRNA molecules expressed in a cell type except for the most highly expressed mRNA species). The invention also provides a method of generating a population of oligonucleotide primers for transcriptome profiling of total RNA from a subject of interest. | 2010-02-04 |
| 20100029512 | FORMING SAMPLE COMBINATIONS USING LIQUID BRIDGE SYSTEMS - The present invention generally relates to methods of constructing liquid bridges and methods of forming predetermined combinations of samples using liquid bridges. | 2010-02-04 |
| 20100029513 | Methods And Compositions For Generating Mixtures Of Nucleic Acid Molecules - In some embodiments, the present disclosure provides methods of making a mixture of nucleic acid molecules, the methods comprising the steps of: synthesizing on a substrate a population of nucleic acid molecules wherein each synthesized nucleic acid molecule comprises a substrate-attached proximal nucleic acid molecule, a distal nucleic acid molecule, and a cleavable linker linking the proximal nucleic acid molecule to the distal nucleic acid molecule, and harvesting distal nucleic acid molecules from the substrate by cleaving the cleavable linker under conditions that do not release the proximal nucleic acid molecule. Related compositions and kits are also provided. | 2010-02-04 |
| 20100029514 | NAPHTHENIC ACID SOLIDS DISSOLVER COMPOSITIONS AND METHODS RELATED THERETO - Methods and compositions are provided for dissolving naphthenic acid solids from oilfield systems. The composition includes glacial acetic acid and a solvent that is soluble in the glacial acetic acid or a solvent in which the glacial acetic acid is soluble. | 2010-02-04 |
| 20100029515 | HYDROCARBON FLUIDS AND METHODS OF USING SAME - A new hydrocarbon fluid composition and methods of using the fluid are disclosed. The fluid is comprised of a liquid hydrocarbon, a phosphate ester, an iron or aluminum salt crosslinker, a hydrocarbon foaming agent and a gas. The fluid can be used in many applications. | 2010-02-04 |
| 20100029516 | FIBER ASSISTED EMULSION SYSTEM - Emulsions, either water-in-oil or oil-in-water, may be formed by combining an aqueous component, a non-aqueous component and a surfactant in combination with fibers. The fibers decrease the time and energy required to form the emulsion and, in some cases, allow emulsion formation that would not be possible with the use of such fibers. | 2010-02-04 |
| 20100029517 | COMPONENTS, TURBOCHARGERS, AND METHODS OF FORMING THE COMPONENTS - Components, turbochargers, and methods of forming components are provided. In an embodiment, by way of example only, a method of forming a component is provided. The method includes applying a plurality of coated particles to a substrate, wherein each coated particle comprises a solid film lubricant particle and a layer surrounding an entire surface of the solid film lubricant particle, each solid film lubricant particle comprises at least one compound, and the layer comprises a coating material having a greater resistance to oxidation than the compound when subjected to a predetermined processing temperature and heating the substrate to the predetermined processing temperature to form a portion of a coating over the substrate. | 2010-02-04 |
| 20100029518 | LUBRICANT WITH NANODIAMONDS AND METHOD OF MAKING THE SAME - A lubricating composition and method of making the same are provided. The lubricating composition comprises a lubricant fluid, water, and carbon nanoparticles comprising nanodiamonds. The method comprises mixing the lubricating composition under high shear followed by ultrasonication. | 2010-02-04 |
| 20100029519 | PERFORMANCE ADDITIVES FOR IMPROVING THE WETTING PROPERTIES OF IONIC LIQUIDS ON SOLID SURFACES - Composition containing at least one ionic liquid and at least one performance additive and if appropriate a solvent and/or of further auxiliaries or additives and its use as wetting agent for solid surfaces. | 2010-02-04 |
| 20100029520 | LUBRICATING OIL COMPOSITION - Provided is a lubricating oil composition of an environmental regulation compliant type, comprising (A) a base oil for a lubricating oil, (B) sulfated oxymolybdenum dithiocarbamate, (C) an acid amide compound, (D) (d1) a fatty acid partial ester compound and/or (d2) an aliphatic amine compound and (E) a specific benzotriazole derivative, wherein a content of the component (B) is 0.02 to 0.1% by mass in terms of molybdenum; a content of the component (C) is 0.2 to 1.0 % by mass; a content of the component (D) is 0.2 to 1.0% by mass; and a content of the component (E) is 0.02 to 0.1% by mass each based on the whole amount of the composition, and it has an excellent friction reducing effect in combination with a high corrosion preventing effect to copper and lead. | 2010-02-04 |
| 20100029521 | GREASE COMPOSITION AND MACHINE ELEMENTS - A grease composition which contains a large amount of thickener, and may prevent a flaking effectively for a long period of time, and machine elements in which the grease composition is filled are provided. A grease composition comprising a thickener and a base oil, characterized in that the thickener contains a diurea compound represented by the Formula (I): | 2010-02-04 |
| 20100029522 | REFRIGERATOR OIL COMPOSITION - A refrigerator oil composition includes: a synthetic base oil; and a partial hydrocarbyl ether of an aliphatic polyhydric alcohol condensate, in which the aliphatic polyhydric alcohol condensate includes a condensate of 4 to 20 molecules of a hindered glycol and/or an aliphatic polyhydric alcohol having 3 to 6 hydroxyl groups. The refrigerator oil composition is preferably used in a compression refrigerator that uses a hydrofluorocarbon, a natural refrigerant such as a hydrocarbon, carbon dioxide, or ammonia, a mixed refrigerant of fluoroiodomethane and propene, an unsaturated fluorinated hydrocarbon, a fluorinated ether, a fluorinated alcohol, a fluorinated ketone, or a mixture thereof as a refrigerant, has a low coefficient of friction, and is excellent in energy-saving property. | 2010-02-04 |
| 20100029523 | LUBRICANTS DERIVED FROM PLANT AND ANIMAL OILS AND FATS - A lubricant from plant and/or animal oils and fats; a method for producing a lubricating oil, and the oil produced thereby. The lubricant comprises a diester produced by epoxidising an animal or plant fat or oil having an iodine number above about 7 and reacting the epoxidised oil or fat with a carboxylic acid anhydride in the presence of a basic catalyst. | 2010-02-04 |
| 20100029524 | GREASE - Grease which includes a base oil containing at least 50% by mass of a specific diester compound of a glycol with a branched carboxylic acid, and a specific diurea compound as a thickener. The grease is excellent in low-temperature performance and has low oil separation tendency. In particular, when used in a rotation transmission device having a built-in one-way clutch, the grease can provide satisfactory clutch engagement performance (intermeshing) at low temperatures and is less apt to cause oil separation under high centrifugal force. | 2010-02-04 |
| 20100029525 | ANTIWEAR HYDRAULIC FLUID COMPOSITION WITH USEFUL EMULSIFYING AND RUST PREVENTION PROPERTIES - Disclosed are antiwear hydraulic fluid compositions comprising (a) a major amount of a base oil of lubricating viscosity and (b) a minor amount of at least one oil soluble detergent additive comprising a salt of an alkyl-substituted hydroxybenzoic acid or a sulfurized derivative thereof, wherein said salt is selected from the group consisting of alkali metal salts, alkaline earth metal salts, ammonium salts or substituted ammonium salts, and further wherein said antiwear hydraulic fluid compositions have a Carboxylate Index of greater than levels disclosed herein. | 2010-02-04 |
| 20100029526 | UREA GREASE COMPOSITION - The present invention aims to offer a urea grease composition which excels in noise performance, has long life at high temperatures and, further, also provides the basic performance of greases such as shear stability and heat resistance, as well as appropriate oil separation properties. The present invention provides a urea grease composition comprising: a diurea compound as shown by the General Formula (A) below: R | 2010-02-04 |
| 20100029527 | Lubricating oil additive and lubricating oil composition containing same - An overbased salt of an oligomerized alkylhydroxyaromatic compound is disclosed, wherein the alkyl group of the alkylhydroxyaromatic compound is derived from an olefin mixture comprising propylene oligomers having an initial boiling point of at least about 195° C. and a final boiling point of no more than about 325° C. as measured by ASTM D86. Also disclosed is a lubricating oil composition containing at least (a) a major amount of an oil of lubricating viscosity and (b) the overbased salt of the oligomerized alkylhydroxyaromatic compound. | 2010-02-04 |
| 20100029528 | Conditioning Shampoo Compositions - An aqueous conditioning shampoo composition comprising an anionic cleansing surfactant and a gel network comprising: (i) a fatty material selected from C | 2010-02-04 |
| 20100029529 | Surfactant having chlorine-capturing ability and anti-discoloration ability and chemical formulation containing the same surfactant - An amphoteric surfactant reduces adverse effects of free chlorine and ensures high color retention of dyed hair, dyed keratin fibers and dyed fabrics made of dyed keratin fibers. The surfactant is represented by the following general formula (1): | 2010-02-04 |
| 20100029530 | Biostatic Medical Cleaning Products - There is disclosed a cleaning composition comprising (i) 0.1 to 10 percent by weight of the cleaning composition of a biofilm removing detergent solution comprising a combination of an alkyl (C 8-18) polysaccharide, a non-ionic surfactant and a nitrogen containing surfactant-biocide (ii) 2 to 80 percent by weight of the cleaning composition of one or more polar solvent (iii) 0.5 to 15 percent by weight of the cleaning composition of one or more primary amine (iv) two or more chelating agents (v) 0.1 to 5.0 percent by weight of the cleaning composition of an alkaline buffer system providing a pH of about 11.5 to 13.3 in aqueous solution (vi) 0.005 to 5.0 percent by weight of the cleaning composition of an alkoxyaminosilane. Also disclosed is a process of cleaning, decontaminating and/or passivating metallic surgical instruments and/or equipment using the composition of the invention. | 2010-02-04 |
| 20100029531 | Nonflammable compositions comprising fluorinated compounds and use of these compositions - The invention relates to non-flammable compositions comprising fluorinated compounds selected from the group consisting of hydrofluoroalkanes, hydrofluoroalkenes, partially or perfluorinated aromatic compounds, hydrofluoroethers or fluoroketones, 1,2-dichloroethylene, especially trans-1,2-dichloroethylene, and a stabilizer. These non-flammable compositions which preferably contain 1,1,1,3,3-pentafluorobutane, can be used especially as solvents for cleaning and defluxing electronic components and for degreasing metals. The compositions further may comprise a propellant, e.g. 1,1,1,2-tetrafluoroethane. These compositions are especially suitable as flushing agent. | 2010-02-04 |
| 20100029532 | AZEOTROPIC COMPOSITIONS COMPRISING FLUORINATED COMPOUNDS FOR CLEANING APPLICATIONS - The present invention relates to compositions comprising fluorinated olefins or fluorinated ketones, and at least one alcohol, halocarbon, hydrofluorocarbon, or fluoroether and combinations thereof. In one embodiment, these compositions are azeotropic or azeotrope-like. In another embodiment, these compositions are useful in cleaning applications as a degreasing agent or defluxing agent for removing oils and/or other residues from a surface. | 2010-02-04 |
| 20100029533 | FLOOR STRIPPER FOR CHEMICALLY-RESISTANT CROSSLINKED FLOOR FINISHES - Floor finishes are stripped or deep scrubbed using a floor stripper/cleaner composition containing a phenyl-substituted alkyl alcohol, an oxygenated swelling solvent other than the phenyl-substituted alkyl alcohol, water, sufficient coupler so that the composition has a single phase, and sufficient saponification agent comprising the reaction product of a fatty acid or fatty ester with a stoichiometric excess of an alkali metal hydroxide or ammonium hydroxide so that the composition has an alkaline pH and has a reduced oily residue after stripping when compared to an otherwise similar composition that does not contain the saponification agent. The composition is useful for removing ultradurable (e.g., crosslinked) floor finishes, especially on flooring substrates that are susceptible to chemical attack. | 2010-02-04 |
| 20100029534 | Cleaning Compositions and Methods - Cleaning compositions are described comprising an aqueous component: an organic solvent; an anionic surfactant; an amine co-surfactant containing either (a) an N-oxide group or (b) a zwitterionic group; and a nonionic surfactant; in a form of a microemulsion or microemulsion preconcentrate. Methods of cleaning a hard surface using such compositions are also described. | 2010-02-04 |
| 20100029535 | Package Comprising a Detergent Composition - A package comprises a detergent composition enclosed by a water-soluble or water-dispersible packaging material. The detergent composition further comprises encapsulated phthalimidoperhexanoic acid (PAP) in granular form having a particle size of from 10-500 μm. | 2010-02-04 |
| 20100029536 | Detergents - Phosphate-free dishwasher detergents which contain a builder, bleaching agents, a nonionic surfactant, and also a) a copolymer comprising i) sulfonic acid group-containing monomers, ii) further ionic and/or nonionic monomer, and b) phosphonate. The detergents have good scale-inhibiting, cleaning and rinsing results which are comparable to those of phosphate-containing dishwasher detergents or even outdo them. | 2010-02-04 |
| 20100029537 | DELIVERY PARTICLE - The present application relates to encapsulated benefit agents, compositions comprising such encapsulated benefit agents and processes for making and using compositions comprising such encapsulated benefit agents that do not require or require a reduced amount of scavenger materials. Such encapsulated benefit agents, compositions comprising such encapsulated benefit agents are processed such that no or lower levels of scavenger materials are required. | 2010-02-04 |
| 20100029538 | One-Step Treatment of Textiles - The present invention is directed to novel compositions and methods for enzymatic one-step pretreatment of cellulosic, cellulosic-containing (e.g., cotton and cotton-containing) and non-cellulosic textiles, fibers and fabrics. Pretreatment comprises scouring and bleaching, and optionally, desizing of the textiles. | 2010-02-04 |
| 20100029539 | DELIVERY PARTICLE - The present application relates to encapsulated benefit agents, compositions comprising such encapsulated benefit agents and processes for making and using compositions comprising such encapsulated benefit agents that do not require or require a reduced amount of scavenger materials. Such encapsulated benefit agents, compositions comprising such encapsulated benefit agents are processed such that no or lower levels of scavenger materials are required. | 2010-02-04 |
| 20100029540 | BIHETEROARYL METAL COMPLEXES AS BLEACH CATALYSTS - Biheteroaryl metal complexes and the use thereof as bleach catalysts are described. | 2010-02-04 |
| 20100029541 | METHOD OF RETAINING THE QUALITY OF 2-METHYL-3-(3,4-METHYLENEDIOXYPHENYL)PROPANAL AND PROCESS FOR PRODUCING THE SAME - The present invention relates to [1] a method for keeping a quality of 2-methyl-3-(3,4-methylenedioxyphenyl)propanal useful as a perfume, which comprises incorporating from 50 to 3000 ppm of 1-acetyl-3,4-methylenedioxybenzene in the 2-methyl-3-(3,4-methylenedioxyphenyl)propanal; [2] a process for producing 2-methyl-3-(3,4-methylenedioxyphenyl)propanal having a content range from 50 to 3000 ppm of 1-acetyl-3,4-methylenedioxybenzene; and [3] 2-methyl-3-(3,4-methylenedioxyphenyl)propanal having a content range from 50 to 3000 ppm of 1-acetyl-3,4-methylenedioxybenzene. | 2010-02-04 |
| 20100029542 | PROTEIN STERILISATION BY RADIATION AND ADDITION OF A STABILISING COMPOSITION - A method of sterilising a protein, comprises exposing to ionising radiation an at least substantially dry composition comprises a protein and a protective compound or combination of protective compounds having both of the following characteristics: (i) a rate of reaction with singlet oxygen greater than 1×10 7 L mol−1 S−1; (ii) being a reducing agent whilst at the same time containing a proton dissociable group with a pKa no more than 3 units from the pH of the composition. The compound having characteristic (i) is selected from histidine, thiamine and tryptophan, the compound having characteristic (ii) is selected from methionine, malate, citrate, lactate and tiron. The radiation is gamma radiation or electron beam, whereby the preferred dose is 15-40 kGy. | 2010-02-04 |
| 20100029543 | METHODS FOR TREATING NUCLEOSIDE-INDUCED PAIN - The present invention is directed to the use of a class of peptide compounds for treating tumor pain, in particular bone cancer pain, for treating chemotherapy-induced pain and for treating nucleoside-induced pain. | 2010-02-04 |
| 20100029544 | Composition - Novel polyallylamine (PAA) based graft polymers are provided, including groups such as cholesteryl, cetyl, palmitoyl, which are adapted to deliver an entity that is normally of poor solubility in an aqueous medium, said entity being such as a drug, peptide, protein, or polynucleotide that is releasably contained within the said polymer, the resulting complex being of nanoparticle range sizes with a T | 2010-02-04 |
| 20100029545 | BORONIC ACID-CONTAINING BLOCK COPOLYMERS FOR CONTROLLED DRUG DELIVERY - Polymeric nanoaggregate drug-delivery compositions including boron-containing copolymers are described. The drug-delivery compositions may further include a therapeutic agent comprising a nucleic acid, a polynucletide, a peptide, a polypeptide, a protein, a pharmaceutical or any combinations thereof. Methods for making the polymeric nanoaggregate compositions including at least one therapeutic agent (for example, insulin) as well as methods for administration of these compositions to mammals are also set forth. The disclosure also describes compositions and methods for controlled drug delivery. Further, polymeric nanoaggregate boron-containing compositions including insulin and methods for monitoring and regulating blood glucose levels of a mammal are also described. The disclosure also describes methods for treatment and/or control of diabetes mellitus by administering polymeric nanoaggregate boron-containing compositions including insulin to a mammal in need. | 2010-02-04 |
| 20100029546 | preparation method of galactosyl-has magnetic nanoparticles containing adriamycin - Preparation of galactose albumin adriamycin magnetic nanoparticles: in order to prepare galactose albumin magnetic nanoparticle, cottonseed oil and magnetic nano powder is needed. Mix galactose albumin, adriamycin and magnetic nanoparticle at a proportion, and get the particle through emulsification in cottonseed oil, heating for solidification, and diethyl ether washing. This invention couples galactose to the surface of nanoparticle to form galactose nanoparticle, which targets actively and passively to improve the drug targeting level to liver. Modifying albumin adriamycin magnetic nanoparticles with galactose enhances its targeting level. | 2010-02-04 |
| 20100029547 | Mvl, an antiviral protein from a cyanobacterium - The present invention relates, e.g., to an isolated polypeptide from a cyanobacterium, | 2010-02-04 |
| 20100029548 | GLYCOPROTEINS PRODUCED IN PLANTS AND METHODS OF THEIR USE - Methods of increasing the yield in plant expression of recombinant proteins comprising: engineering glycosylation sites into cloned genes or cDNAs for proteins using codons that drive post-translational modifications in plants; and engineering the cloned genes or cDNAs to contain a plant secretory signal sequence that targets the gene products (protein) for secretion. The methods result in increased recombinant glycosylated protein yields. Proteins produced according to these methods are disclosed. | 2010-02-04 |
| 20100029549 | SITU SELF-SETTING MINERAL-POLYMER HYBRID MATERIALS, COMPOSITION AND USE THEREOF - The present invention relates to self-setting compositions consisting in admixed liquid and solid components enable the formation of hardened bio-materials having a broad range of properties and performances. The present invention proposes a) a thermo-sensitive self-gelling liquid component, being water-based, comprising at least a polycationic and a phosphate source, wherein the liquid component is a thermo-gelling solution at a pH ranging from 6.5 to 7.4; b) a powder component consisting in at least two calcium phosphate sources. The preferred calcium phosphate source includes apatites, tricalcium phosphates, tetracalcium phosphates and dicalcium phosphates. Both solid and liquid components are admixed to form a flowable slurry that sets in situ into a hardened calcium phosphate based bio-material. | 2010-02-04 |
| 20100029550 | ORGANIC COMPOUNDS - A pharmaceutical composition for parenteral administration of a somatostatin analogue salt of aspartate, e.g. mono- or diaspartate, lactate, succinate, e.g. mono- or disuccinate, acetate, glutamate, e.g. mono- or diglutamate or citrate and water forming a gelling depot system after injection in contact with the body fluid. | 2010-02-04 |
| 20100029551 | Treatment Of Inflammatory Lung Conditions With Aerosolized Macrolide Antibiotics - Provided herein are pharmaceutical compositions comprising an anti-inflammatory macrolide compound suitable for aerosolized administration to the lungs by inhalation, and methods of treating inflammatory lung conditions, particularly those characterized by chronic inflammation, by administering an aerosolized anti-inflammatory macrolide compound to the lungs by inhalation. Also provided are unit dose formulations of an anti-inflammatory macrolide for aerosolized administration to the lungs by inhalation. Advantageously, the described methods and compositions allow for the targeted, localized delivery of anti-inflammatory macrolide compounds throughout the lungs without significant systemic absorption or deposition. | 2010-02-04 |
| 20100029552 | Peptide inhibitors of c-jun dimerization and uses thereof - The present invention provides a method for the screening of nucleic acid fragment expression libraries and selecting encoded peptides based upon their ability to modulate the activity of a target protein or nucleic acid and assume conserved conformations compatible with albeit not reiterative of the target protein or nucleic acid. The present invention also provides methods for the diagnosis and treatment of ischemia. The present invention also provides c-Jun dimerization inhibitory peptides and analogues thereof that are useful for treatment of ischemia. | 2010-02-04 |
| 20100029553 | Microfluidic Device for Controlled Aggregation of Spider Silk - The present invention is directed to a device and method of controlling the phase separation of one or a mixture of two or more spider silk proteins, leading to the defined and controllable assembly of the said silk protein(s) to defined morphologies, such as spheres, nano fibrils, threads, etc. | 2010-02-04 |
| 20100029554 | Composition and Methods for Treatment of Congestive Heart Failure - Provided herein is the use of GLP-1 molecules or agonists and analogs thereof, and the use of exendin molecules or agonists and analogs thereof, including their derivatives and active fragments, for the prevention or treatment of congestive heart failure. Pharmaceutical compositions for use in the methods described herein are also disclosed. Further provided are compositions and methods for the treatment and/or prevention of diabetes mellitus, hyperglycemia, insulin resistance and obesity, and for the reduction of food intake and suppression of appetite of subjects. | 2010-02-04 |
| 20100029555 | G-CSF SITE-SPECIFIC MONO-CONJUGATES - Novel site-specific mono-conjugates of Granulocyte Colony Stimulating Factor (G-CSF) are hereby described, with analogues and derivatives thereof, which stimulate proliferation and differentiation of progenitor cells to mature neutrophiles. These conjugates have been obtained using transglutaminase to covalently and site-specifically bind a hydrophilic, non-immunogenic polymer to a single glutamine residue of the human G-CSF native sequence and analogues thereof. These novel site-specific mono-conjugated derivatives are recommended for therapeutic use since they are stable in solution and exhibit significant biological activity in vitro and a longer bloodstream half-life, as compared to the non-conjugated protein, with a consequent prolonged pharmacological activity. | 2010-02-04 |
| 20100029556 | Stable composition comprising a bone anabolic protein, namely a pthrp analogue, and uses thereof - The present invention provides a storage-stable composition containing a parathyroid hormone-related protein (PTHrP) analogue and methods of using a PTHrP analogue and the PTHrP compositions described herein to treat osteoporosis, to increase bone mass or to increase bone quality. The composition is storage stable, in sterile form, and in general may be stored at room temperature for at least several weeks to allow convenient parenteral administration to human patients. | 2010-02-04 |
| 20100029557 | ALPHA-LACTALBUMIN COMPOSITION - The present invention relates to a pharmaceutical composition comprising monomeric alpha-lactalbumin complex, preferably LAC, which is an active complex of alpha-lactalbumin and a fatty acid or lipid with selective cytotoxic activity. The composition of the invention comprises insignificant amounts of oligomeric/multimeric alpha-lactalbumin complex, preferably LAC. Based on the selective cytotoxicity of the alpha-lactalbumin complex, preferably LAC composition such compositions are suitable for use in the manufacture of medicaments for use in therapy. Medicaments, comprising monomeric LAC are for use in the treatment of bacterial and viral infections and in particular cancer due to the selective cytotoxic activity. The application further relates to methods of producing a composition comprising monomeric alpha-lactalbumin complex, preferably LAC with cytotoxic activity. | 2010-02-04 |
| 20100029558 | Alpha1 proteinase inhibitor peptides methods and use - The invention is directed to the use of peptides that can bind and block the interaction of α1 proteinase inhibitor (α | 2010-02-04 |
| 20100029559 | Method for achieving desired glial growth factor 2 plasma levels - The present invention relates to administering glial growth factor 2 (GGF2) to a patient in need thereof, to achieve serum levels of GGF2 within a desired therapeutic window determined based on the disease or disorder afflicting the patient. In a particular embodiment, the patient is suffering from a disease or disorder associated with reduced levels of myelination and the GGF2 is administered to promote myelination in the patient. | 2010-02-04 |
| 20100029560 | COMPOSITIONS AND METHODS FOR DIAGNOSING, TREATING, AND PREVENTING PROSTATE CONDITIONS - Disclosed are compositions and methods for diagnosing, preventing, and treating prostate cancer and prostate intraepithelial neoplasia (PIN). | 2010-02-04 |
| 20100029561 | AMELIORATING AGENT FOR INSULIN RESISTANCE - The present invention provides an insulin sensitizer and a prophylactic/therapeutic agent for diseases involved by sugar metabolic abnormality, comprising a substance that inhibits the expression or activity of CPSF5 protein and/or a substance that inhibits the expression or activity of CPSF6 protein. Provided as the substances are (a) an antisense nucleic acid against a nucleic acid that encodes CPSF5 (or CPSF6), (b) an siRNA against an RNA that encodes CPSF5 (or CPSF6), (c) a nucleic acid capable of producing an siRNA against an RNA that encodes CPSF5 (or CPSF6), and the like. Also provided is a screening method for an insulin resistance ameliorating substance using a cell that produces CPSF5 and/or CPSF6. | 2010-02-04 |
| 20100029562 | hG31P Expression System - Expression plasmids and expression systems for the expression of human G31P | 2010-02-04 |
| 20100029563 | DERIVATIVES OF GROWTH HORMONE AND RELATED PROTEINS, AND METHODS OF USE THEREOF - The growth hormone supergene family comprises greater than 20 structurally related cytokines and growth factors. A general method is provided for creating site-specific, biologically active conjugates of these proteins. The method involves adding cysteine residues to non-essential regions of the proteins or substituting cysteine residues for non-essential amino acids in the proteins using site-directed mutagenesis and then covalently coupling a cysteine-reactive polymer or other type of cysteine-reactive moiety to the proteins via the added cysteine residue. Disclosed herein are preferred sites for adding cysteine residues or introducing cysteine substitutions into the proteins, and the proteins and protein derivatives produced thereby. Also disclosed are therapeutic methods for using the cysteine variants of the invention. | 2010-02-04 |
| 20100029564 | NOVEL PROCESS OF SOLUBILIZING PROTEIN FROM A PROTEINACEOUS MATERIAL AND COMPOSITIONS THEREOF - The process for solubilizing proteinaceous material of the present invention includes subjecting the proteinaceous material to a sufficient amount of a basic solution to obtain a supernatant that has a basic pH and exposing the supernatant to the basic solution for a sufficient length of time and temperature for hydrolysis to occur. The process also includes cooling the mixture of the supernatant and proteinaceous material and optionally acidifying the mixture. This process may also include recovering the solubilized protein from the supernatant for use in various applications. Also provided herein is a composition of solubilized proteins from eggshell membrane obtained using processes of the present invention. | 2010-02-04 |
| 20100029565 | RECOMBINANT B. pseudomallei ADHESIN PROTEIN AND METHODS AND USES THEREOF - Isolated and/or recombinant adhesin polypeptides from | 2010-02-04 |
| 20100029566 | USE OF AT LEAST ONE BOTULINUM NEUROTOXIN FOR TREATING THE PAIN INDUCED BY THERAPEUTIC TREATMENTS FOR THE AIDS VIRUS - The present invention relates to the use of at least one botulinum neurotoxin for the production of a medicament for treating or preventing pain induced by a medicament used for treating the AIDS virus. | 2010-02-04 |
| 20100029567 | METHOD OF CORRECTING IMBALANCE BETWEEN BONE RESORPTION AND BONE FORMATION AND KITS AND COMPOSITIONS THEREFOR - Compounds, methods, uses, compositions, kits and packages for the treatment of imbalance between bone resorption and bone formation, based on uses of 4-phenyl-2 propionamidotetralin (4-P-PDOT) and analogs, derivatives, prodrugs, precursors thereof, and salts thereof, are described. | 2010-02-04 |
| 20100029568 | TIGHTER-BINDING C-PEPTIDE INHIBITORS OF HIV-1 ENTRY - The invention provides compositions and methods for the treatment of HIV infection, inhibition against drug-resistant strains of HIV-1 and methods of enhancing the anti-HIV potency of peptide inhibitors against drug-resistant strains of HIV-1. In particular, oligomeric C-peptide inhibitors for inhibiting HIV entry into host cells are disclosed. | 2010-02-04 |
| 20100029569 | Pharmaceutical Formulation - The invention relates to aqueous pharmaceutical formulations comprising human growth hormone, histidine, poloxamer, phenol, and mannitol. | 2010-02-04 |
| 20100029570 | PEPTIDE AND TREATMENT FOR HIV-1 INFECTION - A compound of the formula X | 2010-02-04 |
| 20100029571 | NOVEL AND POWERFUL MHC-CLASS II PEPTIDES DERIVED FROM SURVIVIN - The present invention relates to peptides, nucleic acids, and cells for use in the immunotherapy of cancer. The present invention furthermore relates to survivin-derived tumor-associated cytotoxic T cell (CTL) peptide epitopes, alone or in combination with other tumor-associated peptides that serve as active pharmaceutical ingredients of vaccine compositions that stimulate anti-tumor immune responses. The present invention specifically relates to three novel peptide sequences and variants thereof derived from HLA class I and class II molecules of human tumor cells that can be used in vaccine compositions for eliciting anti-tumor immune responses. | 2010-02-04 |
| 20100029572 | Neurotrophic Peptides - The present invention relates to a neurotrophic peptide having an amino acid sequence selected from the group consisting of VG-DGGLFEKKL (SEQ ID No. 1), EDQQVHFTPTEG (SEQ ID No. 2) and IPENEADGMPATV (SEQ ID NO. 3). | 2010-02-04 |
| 20100029573 | Tumor-associated peptides that bind to mhc-molecules - The invention relates to a tumor-associated peptide with an amino acid sequence selected from the group consisting of SEQ ID NO. 1 to SEQ ID NO. 577 from the attached sequence protocol, the peptide being capable of binding to a molecule of the human major histocompatibility complex (MHC) class I. The invention further relates to the use of the peptides for preparation of a drug and for the treatment of tumor diseases and/or adenomatous diseases. Furthermore, a pharmaceutical composition is described comprising at least one of the peptides. | 2010-02-04 |
| 20100029574 | COSMETIC COMPOSITIONS - The present invention generally features novel cosmetic skin and hair care compositions for enhancing the appearance of eyelashes and eyebrows. Specifically, the topical skin and hair care compositions of the invention contain a concentration of at least one of pentapeptide-17 tetrapeptide-12 that provide for thicker, longer and more voluminous appearing eyelashes and eyebrows. The cosmetic formulations of the invention may further include cosmetically acceptable vehicle(s) and/or other skin and hair conditioning agents. | 2010-02-04 |
| 20100029576 | Diazoxide for the treatment of Friedreich's Ataxia - A pharmaceutical preparation treats Friedreich's ataxia and treats or prevents pathologies related thereto. In particular, the pharaceutical preparation concerns the use of diazoxide or 7-chloro-3-methyl-4H-1,2,4 benzothiadiazine 1,1-dioxide, in combination with glucose and/or leucine, for the treatment of Friedreich's ataxia (FRDA) and for the treatment or prevention of pathologies related thereto. | 2010-02-04 |
| 20100029577 | Chiral separation, characterization and biological action of optically active isomers of digoxin - Disclosed herein is the method for separation of enantiomers or isomers of digoxin. These isomers are to be used-in the treatment of heart failure without adverse or unneeded cardiac actions in humans. Additionally what is claimed is an isolate with less or no cardiac contractile effect but with AV node slowing such that the composition would be an effective therapy for the control of the ventricular response in atrial fibrillation. Also disclosed are methods for assaying these isomeric compounds present in biological fluids to enable the separation of pharmacologic actions. | 2010-02-04 |
| 20100029578 | Methods of Treating Atrial Fibrillation with P38 Inhibitor Compounds - The invention disclosed herein relates generally to compounds and methods useful in treating or preventing atrial fibrillation (AF). | 2010-02-04 |
| 20100029579 | ANTIVIRAL COMPOUNDS - The invention provides a new class of compounds exhibiting an inhibitory effect on neuraminidase (NA), hemagglutinin (HA) and structural M | 2010-02-04 |
| 20100029580 | Method for Diagnosing Non-Small Cell Lung Carcinoma - The present invention relates to the constitutive activity of the Hedgehog pathway in non-small cell lung carcinoma (NSCLC). A method for diagnosing NSCLC by detecting the level of a component of the Hedgehog pathway is provided, as is a method for identifying subjects that will respond positively to treatment with a Hedgehog pathway antagonist. Methods for treating subjects with cancer or cancers resistant to Hedgehog pathway antagonists are also provided. | 2010-02-04 |
| 20100029581 | NUTRITIONAL SUPPLEMENT - A nutritional supplement comprises about 2 parts roasted, ground flaxseed, about 2 parts of chick pea flour, about 1.5-2 parts of whole wheat or brown rice flour, about 1 part of raw, ground almonds and optionally, about 0.5-1 part of whole wheat bran. The supplement may additionally contain one or both of raw blue agave nectar and sunflower oil. The supplement may also contain cardamom and/or ginger. The nutritional supplement comprises at least about 1.5 grams of Omega-3 fatty acids, less than about 1.5 grams (g) of glucose, and less than about 0.6 g of sucrose in a serving of about 2 ounces (about 59 ml). A method of supplementing the nutrition of an individual comprises administering the nutritional supplement to the individual. | 2010-02-04 |
| 20100029582 | Anticoagulant Antithrombotic Dual Inhibitors Comprising a Biotin Label - The present invention relates compounds of the formula: oligosaccharide-spacer-(GpIIb/IIIa antagonist), wherein the oligosaccharide is a negatively charged oligosaccharide residue comprising four to twenty five monosaccharide units, the charge being compensated by positively charged counterions, and wherein the oligosaccharide residue is derived from an oligosaccharide which has (AT-II mediated) anti-Xa activity per se; the spacer is a bond or an essentially pharmacologically inactive linking residue; the GpIIb/IIIa antagonist is a residue mimicking the RGD and/or K(QA)GD fragment of fibrinogen, comprising a carboxylate moiety and a basic moiety located within the residue at a distance of 10-20 Å from each other; or a pharmaceutically acceptable salt thereof or a prodrug or a solvate thereof; wherein the compound of formula I further comprises at least one covalent bond with a biotin label or an analogue thereof. The compounds of the invention have antithrombotic activity and can be used in treating or preventing thrombotic diseases. The antithrombotic activity of the compound of this invention can be neutralized in case of emergency upon administration of avidin, streptavidin and analogues thereof having high biotin affinity. | 2010-02-04 |
| 20100029583 | PROCESS FOR OBTAINING AN ACTIVE INGREDIENT WITH AN IMMEDIATE TENSOR EFFECT ON THE SKIN, ACTIVE INGREDIENT AND COMPOSITIONS - The invention relates to a method for obtaining an active ingredient having an immediate anti-wrinkle and skin-tensioning effect, characterised in that it comprises extracting and purifying high molecular weight polysaccharides from oat bran and/or fibres and/or grains, and solutioning and stabilising the polysaccharides in water. The invention also relates to the product thus obtained, to uses thereof, and to cosmetic compositions containing this active ingredient. | 2010-02-04 |
| 20100029584 | PROCESS FOR PRODUCING A CELLULOSE-BASED FILM TO BE USED FOR SKIN AND TISSUE LESIONS - The process for producing a cellulose film, to be used for covering, regenerating, repairing and healing of skin and tissue lesions, such as sores, ulcers, burns, wounds etc. by means of cultivation, in a culture medium comprising nitrogen and carbon sources, of microorganisms comprising the | 2010-02-04 |
| 20100029585 | TOLL-LIKE RECEPTOR AGONIST FORMULATIONS AND THEIR USE - The present invention is directed generally to stable formulations of a TLR agonist preferably a TLR7 or a TLR8 agonist, for use in the treatment of cancer, preferably solid tumors and lymphomas. Specifically, the present invention is directed to stable formulations of up to 50 mg/ml of a TLR agonist which comprise a cyclodextrin. | 2010-02-04 |
| 20100029586 | Packaging for a Fabric softening Composition - A packaged product comprising packaging in combination with a fabric softening composition incorporating a skin benefit agent as an ingredient to enable the fabric softening composition to render textile fabrics treated with the composition capable of delivering the skin benefit agent to the skin with which the fabrics come into contact, characterised in that the packaging incorporates tactile cues ( | 2010-02-04 |
| 20100029587 | CYCLIC SILOXANES AND THEIR USE - The invention relates to cyclic siloxanes in which organically modifying groups are bonded to the silicon atom via an oxygen atom (SiOC linkage), and to their use in the production of polyesterpolyurethane and as additive for enhancing the activity of biocides and pesticides. | 2010-02-04 |
| 20100029588 | SUBSTITUTED PHENYLAMIDINES AND THE USE THEREOF AS FUNGICIDES - The present invention relates to oxime ether-, hydrazone- or azomethine-substituted phenylamidines of the general formula (I), to a process for their preparation, to the use of the amidines according to the invention for controlling unwanted microorganisms and also to a composition for this purpose, comprising the amidines according to the invention. Furthermore, the invention relates to a method for controlling unwanted microorganisms by applying the compounds according to the invention to the microorganisms and/or their habitat. | 2010-02-04 |
| 20100029589 | 4,5-DIHYDRO-OXAZOL-2YL DERIVATIVES - The invention relates to compounds of formula I | 2010-02-04 |
| 20100029590 | METHODS FOR TREATING OR PREVENTING HEMORRHAGIC CYSTITIS USING A GLYCEROPHOSPHATE SALT - Glycerophosphate salts have been found to mitigate the syndromes or conditions of discomfort associated with hem-orrhagic cystitis. Therefore, methods are provided for treating or preventing the syndromes or conditions of discomfort associated with hemorrhagic cystitis using a glycerophosphate salt, hi particular, methods are provided for treating or preventing the syndromes or conditions of discomfort associated with hemorrhagic cystitis using calcium glycerophosphate (CGP). | 2010-02-04 |
| 20100029591 | COMBINATIONS OF A PYRIMIDINE CONTAINING NNRTI WITH RT INHIBITORS - The present invention concerns combinations of a pyrimidine containing NNRTI with nucleoside reverse transcriptase inhibitors and/or nucleotide reverse transcriptase inhibitors useful for the treatment of HIV infected patients or for the prevention of HIV transmission or infection. | 2010-02-04 |
| 20100029592 | DEUTERIUM-ENRICHED FOSAPREPITANT - The present application describes deuterium-enriched fosaprepitant, pharmaceutically acceptable salt forms thereof, and methods of treating using the same. | 2010-02-04 |
| 20100029593 | CALCIUM/SODIUM SALT OF INOSITOL TRIPYROPHOSPHATE AS AN ALLOSTERIC EFFECTOR OF HEMOGLOBIN - The present invention relates to mixed calcium/sodium salt of inositol tripyrophosphate, methods of preparing and methods of use. The mixed calcium/sodium salt may be a monocalcium tetrasodium salt of inositol tripyrophosphate. Methods of use include administering the above salts in an effective amount to treat diseases caused by hypoxia or other conditions associated with inadequate function of the lungs or circulatory system, such as various types of cancer and Alzheimer's disease. | 2010-02-04 |
| 20100029594 | CALCIUM/SODIUM SALT OF INOSITOL TRIPYROPHOSPHATE AS AN ALLOSTERIC EFFECTOR OF HEMOGLOBIN - The present invention relates to mixed calcium/sodium salt of inositol tripyrophosphate, methods of preparing and methods of use. The mixed calcium/sodium salt may be a monocalcium tetrasodium salt of inositol tripyrophosphate. Methods of use include administering the above salts in an effective amount to treat diseases caused by hypoxia or other conditions associated with inadequate function of the lungs or circulatory system, such as various types of cancer and Alzheimer's disease. | 2010-02-04 |
| 20100029595 | METHOD OF TREATING OR PREVENTING OSTEOPOROSIS COMPRISING ADMINISTERING TO A PATIENT IN NEED THEREOF AN EFFECTIVE AMOUNT OF PHARMACEUTICAL COMPOSITION COMPRISING BENZAMIDINE DERIVATIVES OR THEIR SALTS, AND ALENDRONIC ACID OR ITS SALT - The present invention relates to a pharmaceutical composition for preventing and treating osteoporosis, comprising N-hydroxy-4-{5-[4-(5-isopropyl-2-methyl-1,3-thiazol-4-yl)phenoxy]pentoxy}benzamidine, 4-{5-[4-(5-isopropyl-2-methyl-1,3-thiazol-4-yl)phenoxy]pentoxy}benzamidine, or salts thereof, and alendronic acid or a salt thereof. | 2010-02-04 |
| 20100029596 | METHOD OF TREATING OR PREVENTING OSTEOPOROSIS COMPRISING ADMINISTERING TO A PATIENT IN NEED THEREOF AN EFFECTIVE AMOUNT OF PHARMACUETICAL COMPOSITION COMPRISING BENZAMIDINE DERIVATIVE OR IT'S SALT, AND BISPHOSPHONATE - The present invention provides a method of treating or preventing osteoporosis comprising administering to a patient in need thereof an effective amount of pharmaceutical composition comprising benzamidine derivative or its salt, and bisphosphonate for the purpose of using simultaneously, separately, or sequentially as active ingredients. As a prophylactic or therapeutic composition for osteoporosis, the combination treatment of the benzamidine derivative and the bisphosphonate compound exhibits excellent inhibitory effect on osteoclast differentiation than the total effect of each individual treatment, thereby being used for the prevention or treatment of osteoporosis. | 2010-02-04 |
